Efficacy of stereotactic ablative radiotherapy (SABR) during anti-PD-1 in oligoprogressive non-small cell lung cancer and melanoma—a prospective multicenter observational study pointing out new unmet needs

Research output: Contribution to journalComment/Letter to the editorAcademic

1 Citation (Scopus)
Original languageEnglish
Pages (from-to)688-691
Number of pages4
JournalTRANSLATIONAL CANCER RESEARCH
Volume12
Issue number3
DOIs
Publication statusPublished - 2023

Keywords

  • Checkpoint inhibitors
  • Response Evaluation Criteria in Solid Tumors (RECIST)
  • abscopal response
  • oligoprogression
  • radiotherapy

Cite this